CORE LABORATORIES ($CLB) posted quarterly earnings results on Wednesday, October 22nd. The company reported earnings of $0.22 per share, beating estimates of $0.19 by $0.03. The company also reported revenue of $134,520,000, beating estimates of $132,613,000 by $1,907,000.
You can see Quiver Quantitative's $CLB stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
CORE LABORATORIES Hedge Fund Activity
We have seen 99 institutional investors add shares of CORE LABORATORIES stock to their portfolio, and 87 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARIEL INVESTMENTS, LLC added 2,634,438 shares (+25.5%) to their portfolio in Q2 2025, for an estimated $30,348,725
- VANGUARD GROUP INC removed 937,528 shares (-17.3%) from their portfolio in Q2 2025, for an estimated $10,800,322
- BOSTON TRUST WALDEN CORP removed 610,889 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $7,037,441
- MILLENNIUM MANAGEMENT LLC added 279,926 shares (+663.9%) to their portfolio in Q2 2025, for an estimated $3,224,747
- STATE STREET CORP added 228,661 shares (+11.8%) to their portfolio in Q2 2025, for an estimated $2,634,174
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 223,587 shares (-20.4%) from their portfolio in Q2 2025, for an estimated $2,575,722
- ROYCE & ASSOCIATES LP removed 198,827 shares (-20.5%) from their portfolio in Q2 2025, for an estimated $2,290,487
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
CORE LABORATORIES Price Targets
Multiple analysts have issued price targets for $CLB recently. We have seen 2 analysts offer price targets for $CLB in the last 6 months, with a median target of $12.5.
Here are some recent targets:
- Stephen Gengaro from Stifel set a target price of $12.0 on 07/16/2025
- Scott Gruber from Citigroup set a target price of $13.0 on 05/13/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
